Full Breakdown
FDA Considers Changes to Dietary Supplement Warning Labels
12/16/2025, 1:36:36 AM
Proposed Rule Change Overview
The Food and Drug Administration (FDA) is contemplating a significant alteration to the labeling requirements for dietary supplements, which could reduce the frequency of mandatory health disclaimers on packaging. Currently, a 1994 federal law mandates that supplement companies include a disclaimer stating, “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease,” whenever health claims are made. Under the proposed changes, companies would still be required to include this disclaimer at least once, but it would no longer need to accompany every health claim, potentially making such warnings less noticeable.
Implications of the Proposed Change
Kyle Diamantas, head of the FDA’s food division, indicated that the agency has rarely enforced the existing labeling rule and that the proposed change aims to reduce label clutter and associated costs for manufacturers. He noted that the FDA would not enforce the current requirement while reviewing the policy. This proposal comes at a time when over three-quarters of Americans reportedly take dietary supplements, with approximately 100,000 products available in the U.S. market.
Expert Opinions and Concerns
Experts have raised concerns regarding the potential implications of this rule change. Dr. Pieter Cohen, an associate professor of medicine at Harvard Medical School, warned that this could lead to increasingly lax labeling practices, suggesting that the disclaimer might eventually only need to appear on the back of the product or in smaller print. Scott Gottlieb, a former FDA commissioner, expressed uncertainty about the impact on consumers, noting that less prominent disclaimers could lead to them being overlooked.
Dr. Cohen also highlighted the risks associated with the lack of pre-market review for dietary supplements, citing a 2023 study he authored which found that nearly 90% of melatonin gummy brands were inaccurately labeled. He emphasized that this inconsistency undermines consumers' ability to understand the true health effects of these products.
Industry Response
The Council for Responsible Nutrition, a trade group representing the supplement industry, expressed support for the FDA's proposed clarification on warning labels. Steve Mister, the group's president and CEO, stated that a single disclaimer linked to health claims with an asterisk or similar symbol would suffice to inform consumers and fulfill the intent of federal law.
Official Statements
Andrew Nixon, a spokesperson for the Department of Health and Human Services, which oversees the FDA, asserted that the proposed changes would not hinder consumers' ability to notice warnings, claiming that “a growing number of Americans are paying closer attention to product labels.”
Conflicting Reports & Gaps
While proponents of the rule change argue that it will streamline labeling, critics like Dr. Cohen contend that it could further obscure important health information. The lack of clarity regarding when the rule change might take effect also remains a point of uncertainty.
Verbatim Quotes
“Then you start saying things like, ‘We only need it on the actual bottle,’” — Dr. Pieter Cohen, Associate Professor of Medicine, Harvard Medical School
“This further undermines the ability of consumers to understand the true health effects,” — Dr. Pieter Cohen, Associate Professor of Medicine, Harvard Medical School
“ Dietary supplements are popular among figures tied to the Make America Healthy Again movement.” — NBC News Report
